• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    REPAY Appoints New Chief Financial Officer

    8/11/25 4:06:00 PM ET
    $CNDT
    $FI
    $IART
    $MRK
    Real Estate
    Real Estate
    Real Estate
    Real Estate
    Get the next $CNDT alert in real time by email

    Repay Holdings Corporation (NASDAQ:RPAY) ("REPAY" or the "Company"), a leading provider of integrated payment processing solutions, today announced the appointment of Robert Houser as Chief Financial Officer of the Company, effective September 8, 2025.

    "We are extremely excited to welcome Rob to REPAY. Rob brings over a decade of divisional CFO and operational experience within the payment industry to help him contribute immediately. Rob has held key strategic roles across his career and will be a great partner in running our company," said John Morris, Co-Founder and CEO.

    Most recently, Rob served as the Group CFO of the Public Sector and Advisor at Conduent Incorporated (NASDAQ:CNDT) ("Conduent"). He previously served as Conduent's Global Head of Strategy, Corporate Development and Advisor to CEO. Prior to Conduent, Rob spent seven years at Fiserv, Inc. (NYSE:FI) holding positions as Senior Vice President, General Manager, and CFO across several divisions. Prior to Fiserv, he was the Global Head of FP&A and Investor Relations at Integra Lifesciences, Inc. (NASDAQ:IART). He previously held various finance, accounting, and strategy roles at Firmenich, Inc, Bristol-Myers Squibb Co. (NYSE:NMY), and Merck & Co Inc. (NYSE:MRK). Rob began his career as an auditor for KPMG LLP, and he earned his MBA and bachelor's degree in accounting from Rider University.

    "With Rob's appointment, interim CFO Thomas Sullivan will return to his role as Chief Accounting Officer. We are extremely grateful for Thomas's help in managing the finance organization over the past several months and the entire REPAY team for supporting the company through the CFO transition," said John Morris.

    About REPAY

    REPAY provides integrated payment processing solutions to verticals that have specific transaction processing needs. REPAY's proprietary, integrated payment technology platform reduces the complexity of electronic payments for clients, while enhancing the overall experience for consumers and businesses.

    Forward-Looking Statements

    This communication contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about REPAY's expectations with respect to the announced leadership changes. Such forward-looking statements are based upon the current beliefs and expectations of REPAY's management and are inherently subject to significant business, economic and competitive uncertainties and contingencies, many of which are difficult to predict and generally beyond REPAY's control, including, without limitation, the factors described in REPAY's reports filed with the U.S. Securities and Exchange Commission. Actual results and the timing of events may differ materially from the results anticipated in these forward-looking statements. All information set forth herein speaks only as of the date hereof in the case of information about REPAY or the date of such information in the case of information.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250811411111/en/

    Investor Relations for REPAY:

    [email protected]



    Media Relations for REPAY:

    Kristen Hoyman

    [email protected]

    Get the next $CNDT alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CNDT
    $FI
    $IART
    $MRK

    CompanyDatePrice TargetRatingAnalyst
    Fiserv Inc.
    $FI
    7/21/2025Sell → Neutral
    Monness Crespi & Hardt
    Fiserv Inc.
    $FI
    7/17/2025Buy
    Deutsche Bank
    Fiserv Inc.
    $FI
    6/2/2025$181.00Buy
    Truist
    Merck & Company Inc.
    $MRK
    5/14/2025$84.00Buy → Neutral
    Citigroup
    Merck & Company Inc.
    $MRK
    4/22/2025$85.00Neutral
    Cantor Fitzgerald
    Fiserv Inc.
    $FI
    4/17/2025$150.00Neutral → Sell
    Redburn Atlantic
    Fiserv Inc.
    $FI
    4/9/2025$145.00Neutral → Sell
    Monness Crespi & Hardt
    Fiserv Inc.
    $FI
    4/2/2025$260.00Neutral → Buy
    Goldman
    More analyst ratings

    $CNDT
    $FI
    $IART
    $MRK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Fiserv upgraded by Monness Crespi & Hardt

    Monness Crespi & Hardt upgraded Fiserv from Sell to Neutral

    7/21/25 8:07:58 AM ET
    $FI
    Real Estate

    Deutsche Bank resumed coverage on Fiserv

    Deutsche Bank resumed coverage of Fiserv with a rating of Buy

    7/17/25 9:24:17 AM ET
    $FI
    Real Estate

    Truist initiated coverage on Fiserv with a new price target

    Truist initiated coverage of Fiserv with a rating of Buy and set a new price target of $181.00

    6/2/25 8:51:54 AM ET
    $FI
    Real Estate

    $CNDT
    $FI
    $IART
    $MRK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Essig Stuart disposed of $2,724,000 worth of shares (200,000 units at $13.62) and acquired $2,724,000 worth of shares (200,000 units at $13.62), decreasing direct ownership by 15% to 1,152,236 units (SEC Form 4)

    4 - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Issuer)

    8/18/25 4:43:39 PM ET
    $IART
    Medical/Dental Instruments
    Health Care

    EVP,Chief Info&Digital Officer Williams David Michael exercised 17,119 shares at a strike of $79.29 and covered exercise/tax liability with 8,432 shares, increasing direct ownership by 36% to 33,013 units (SEC Form 4)

    4 - Merck & Co., Inc. (0000310158) (Issuer)

    8/5/25 8:46:15 AM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Marketing Officer Guindo Chirfi exercised 36,903 shares at a strike of $79.29 and covered exercise/tax liability with 18,175 shares, increasing direct ownership by 27% to 89,234 units (SEC Form 4)

    4 - Merck & Co., Inc. (0000310158) (Issuer)

    8/5/25 8:43:24 AM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CNDT
    $FI
    $IART
    $MRK
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Fiserv Inc.

    SCHEDULE 13G/A - FISERV INC (0000798354) (Subject)

    8/14/25 1:07:20 PM ET
    $FI
    Real Estate

    Amendment: SEC Form SCHEDULE 13G/A filed by Repay Holdings Corporation

    SCHEDULE 13G/A - Repay Holdings Corp (0001720592) (Subject)

    8/14/25 9:22:28 AM ET
    $RPAY
    Real Estate

    Amendment: SEC Form SCHEDULE 13G/A filed by Repay Holdings Corporation

    SCHEDULE 13G/A - Repay Holdings Corp (0001720592) (Subject)

    8/13/25 9:03:59 PM ET
    $RPAY
    Real Estate

    $CNDT
    $FI
    $IART
    $MRK
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Agadi Harshavardhan V bought $281,000 worth of shares (100,000 units at $2.81) (SEC Form 4)

    4 - CONDUENT Inc (0001677703) (Issuer)

    6/20/25 11:34:48 AM ET
    $CNDT
    Real Estate

    Amendment: President and CEO Skelton Clifford bought $101,700 worth of shares (45,000 units at $2.26), increasing direct ownership by 1% to 4,383,552 units (SEC Form 4)

    4/A - CONDUENT Inc (0001677703) (Issuer)

    5/19/25 9:56:21 PM ET
    $CNDT
    Real Estate

    President Alias Shaler bought $490 worth of shares (118 units at $4.15) (SEC Form 4)

    4 - Repay Holdings Corp (0001720592) (Issuer)

    5/16/25 5:00:19 PM ET
    $RPAY
    Real Estate

    $CNDT
    $FI
    $IART
    $MRK
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Ifinatamab Deruxtecan Granted Breakthrough Therapy Designation by U.S. FDA for Patients with Pretreated Extensive-Stage Small Cell Lung Cancer

    Data from IDeate-Lung01 trial will be presented at upcoming IASLC 2025 World Conference on Lung Cancer First Breakthrough Therapy Designation for Daiichi Sankyo and Merck's ifinatamab deruxtecan based on IDeate-Lung01 phase 2 trial, with support from IDeate-PanTumor01 phase 1/2 trial Fourteenth Breakthrough Therapy Designation granted by FDA across the oncology portfolio of Daiichi Sankyo Ifinatamab deruxtecan (I-DXd) has been granted Breakthrough Therapy Designation (BTD) by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with extensive-stage small cell lung cancer with disease progression on or after platinum-based chemotherapy. Ifinatamab derux

    8/18/25 7:00:00 AM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Health Canada Approves KEYTRUDA® for Patients with Resectable Locally Advanced Head & Neck Squamous Cell Carcinoma Tumours that are PD-L1 (CPS) Positive as Neoadjuvant Treatment, Continued as Adjuvant Treatment Combined With Radiotherapy With or Without Cisplatin Then as Monotherapy

    Approval is based on KEYNOTE-689 Phase III Clinical Trial Results KIRKLAND, QC, Aug. 13, 2025 /CNW/ -- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that Health Canada has granted approval for KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, for the treatment of adult patients with resectable locally advanced head and neck squamous cell carcinoma (HNSCC) whose tumours express PD-L1 (Combined Positive Score [CPS] ≥ 1), as determined by a validated test, as neoadjuvant treatment as monotherapy, continued as adjuvant treatment in combination with radiotherapy (RT) with or without cisplatin and then as monotherapy.

    8/13/25 7:00:00 AM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    KEYTRUDA® (pembrolizumab) plus Padcev® (enfortumab vedotin-ejfv) Significantly Improved Event-Free and Overall Survival and Pathologic Complete Response Rate for Certain Patients with Muscle-Invasive Bladder Cancer When Given Before and After Surgery

    First and only systemic therapy to improve survival when used before and after surgery for patients with MIBC who are ineligible for cisplatin-based chemotherapy First ever positive Phase 3 study in this cisplatin-ineligible patient population, representing significant advancement in MIBC Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced positive topline results from the Phase 3 KEYNOTE-905 trial (also known as EV-303) in patients with muscle-invasive bladder cancer (MIBC) who are ineligible for cisplatin-based chemotherapy. In this study, KEYTRUDA® (pembrolizumab) plus Padcev (enfortumab vedotin-ejfv), given before and after surgery (radical cystectom

    8/12/25 5:33:00 AM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CNDT
    $FI
    $IART
    $MRK
    Leadership Updates

    Live Leadership Updates

    View All

    REPAY Appoints New Chief Financial Officer

    Repay Holdings Corporation (NASDAQ:RPAY) ("REPAY" or the "Company"), a leading provider of integrated payment processing solutions, today announced the appointment of Robert Houser as Chief Financial Officer of the Company, effective September 8, 2025. "We are extremely excited to welcome Rob to REPAY. Rob brings over a decade of divisional CFO and operational experience within the payment industry to help him contribute immediately. Rob has held key strategic roles across his career and will be a great partner in running our company," said John Morris, Co-Founder and CEO. Most recently, Rob served as the Group CFO of the Public Sector and Advisor at Conduent Incorporated (NASDAQ:CNDT)

    8/11/25 4:06:00 PM ET
    $CNDT
    $FI
    $IART
    Real Estate
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Conduent Announces Board Leadership Transition

    Harsha V. Agadi Named Chairman, Succeeds Scott Letier Conduent Incorporated (NASDAQ:CNDT), a global technology-driven business solutions and services company, today announced the appointment of Harsha V. Agadi as Chairman of its Board of Directors, effective August 6. He succeeds Scott Letier, who now chairs the Board's Audit Committee. Mr. Agadi joined Conduent's Board in 2025 and previously led its Audit Committee. Mr. Letier has served as a director since 2018 and as Chairman since 2021. These leadership changes are part of the Board's practice of rotating board roles and commitment to strategic governance, as noted in the company's Form 8-K filing on June 25. "We're pleased to wel

    8/6/25 7:45:00 AM ET
    $CNDT
    Real Estate

    Fiserv Announces the Appointment of Stephanie Cohen to Board of Directors

    Fiserv, Inc. (NYSE:FI), a leading global provider of payments and financial services technology solutions, today announced the appointment of Stephanie Cohen to its Board of Directors. Cohen serves as Chief Strategy Officer at Cloudflare, a leading cloud connectivity company, enhancing the security, performance, and reliability of websites and applications for millions of global clients including large brands, small businesses, nonprofit organizations and governments. Cohen joined Cloudflare in 2024 and is responsible for driving the company's key initiatives including the future of Cloudflare's network, artificial intelligence, international expansion and deepening relationships with larg

    3/17/25 7:30:00 AM ET
    $FI
    Real Estate

    $CNDT
    $FI
    $IART
    $MRK
    Financials

    Live finance-specific insights

    View All

    REPAY Reports Second Quarter 2025 Financial Results

    Sequential Improvement in Growth and Strong Free Cash Flow Conversion in Q2 Reiterates 2025 Outlook for Accelerating Growth in Q4 Repurchased 4.8 million shares for $22.6 million during Q2 Repay Holdings Corporation (NASDAQ:RPAY) ("REPAY" or the "Company"), a leading provider of vertically-integrated payment solutions, today reported financial results for its second quarter ended June 30, 2025. Second Quarter 2025 Financial Highlights ($ in millions)   Q2 2024   Q3 2024   Q4 2024   Q1 2025   Q2 2025 Revenue   $ 74.9     $ 79.1     $ 78.3

    8/11/25 4:05:00 PM ET
    $RPAY
    Real Estate

    Conduent Reports Second Quarter 2025 Financial Results

    News from Conduent Key Q2 2025 Highlights Revenue and Adj. Revenue(1): $754MPre-tax Income (Loss): $(38)MAdj. EBITDA Margin(1): 4.9%New Business Signings ACV(2): $150MNet ARR Activity Metric(2) (TTM): $63M FLORHAM PARK, N.J., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Conduent Incorporated (NASDAQ:CNDT), a global technology-led business process solutions and services company, today announced its second quarter 2025 financial results. Cliff Skelton, Conduent President and Chief Executive Officer, stated, "Q2 marks another quarter of progress on our journey. We exceeded expectations for Adjusted EBITDA and Adjusted EBITDA margin. Q2 Revenue was in line with guidance and while often affected by se

    8/6/25 8:01:17 AM ET
    $CNDT
    Real Estate

    Integra LifeSciences Reports Second Quarter 2025 Financial Results

    PRINCETON, N.J., July 31, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, today reported financial results for the second quarter ending June 30, 2025. Second Quarter 2025 Highlights Second quarter revenues exceeded guidance; adjusted earnings per diluted share (EPS) at the top end of the rangeSecond quarter revenues of $415.6 million decreased (0.6)% on a reported basis and (1.4)% on an organic basis compared to the prior year.Second quarter GAAP earnings per diluted share of $(6.31), compared to $(0.16) in the prior year primarily reflecting a goodwill impairment charge of $511 million, recorded during t

    7/31/25 6:00:00 AM ET
    $IART
    Medical/Dental Instruments
    Health Care

    $CNDT
    $FI
    $IART
    $MRK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Repay Holdings Corporation

    SC 13G - Repay Holdings Corp (0001720592) (Subject)

    11/14/24 5:17:53 PM ET
    $RPAY
    Real Estate

    Amendment: SEC Form SC 13G/A filed by Conduent Incorporated

    SC 13G/A - CONDUENT Inc (0001677703) (Subject)

    11/14/24 1:28:32 PM ET
    $CNDT
    Real Estate

    Amendment: SEC Form SC 13G/A filed by Fiserv Inc.

    SC 13G/A - FISERV INC (0000798354) (Subject)

    11/14/24 1:22:34 PM ET
    $FI
    Real Estate